Skip to contentA
Autolus Therapeutics plc
A
AUTLAutolus Therapeutics plc Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$24.29M$24.29Mderived+83,655.2% vs Q4 2024 Net Income-$90.33M-$90.33MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Autolus Therapeutics plc · CIK 1730463 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$72,466,000N/M Operating Cash Flowderived-$67,323,000N/M Free Cash Flowderived-$66,438,000N/M Margins · derivedOperating margin-298.3%+261301.7 pt vs Q4 2024
Net margin-371.9%+94821.2 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 27, 2026 · 86 d after period end